Bausch + Lomb shares popped following a report that the eyecare company is considering selling itself, to separate from its ...

Financial writers report on private equity interest in a potential takeover of Bausch & Lomb, with firms like Blackstone and ...

Bausch Health's debt burden and potential bankruptcy risks are mitigated by the likely sale of Bausch + Lomb, which could fetch a premium price. Bausch + Lomb's stable business and the recent ...

Bausch + Lomb is assessing interest from potential buyers as a way around the roadblock, the FT wrote. The company had a market cap of $6.27 billion on Monday.

The Financial Times reported Bausch + Lomb is in talks with advisors to potentially sell itself. It had formerly sought to spin off from parent Bausch Health in a stock-for-stock deal. But Bausch ...

NEWS Bausch & Lomb Sues Competition Over Copycat Formulation and 'Confusingly Similar' Product Name This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases ...

Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a ...

This week, the Federal Reserve's decision to reduce interest rates by 50 basis points boosted share prices across the ...

Analyst Glen Santangelo of Jefferies reiterated a Buy rating on Bausch Health Companies (BHC – Research Report), reducing the price ...

Eye-care company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial ...

Bausch + Lomb BLCO shares ended the last trading session 14.5% higher at $17.80. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.